Get the Stockscreener App
113.05
2.07%
2.29
Cidara Therapeutics Inc stock is traded at $113.05, with a volume of 1.60M.
It is up +2.07% in the last 24 hours and up +78.20% over the past month.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
See More
Previous Close:
$110.76
Open:
$116.4
24h Volume:
1.60M
Relative Volume:
2.15
Market Cap:
$2.87B
Revenue:
$302.00K
Net Income/Loss:
$-117.10M
P/E Ratio:
-10.16
EPS:
-11.13
Net Cash Flow:
$-129.13M
1W Performance:
+10.84%
1M Performance:
+78.20%
6M Performance:
+561.50%
1Y Performance:
+974.62%
1-Day Range:
$110.86
$121.21
1-Week Range:
$96.35
$121.21
52-Week Range:
$10.14
$121.21
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Name
Cidara Therapeutics Inc
Sector
Industry
Phone
858-752-6170
Address
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Compare CDTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
113.05 | 2.81B | 302.00K | -117.10M | -129.13M | -11.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | JP Morgan | Overweight |
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| Mar-12-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jan-27-25 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Nov-08-24 | Initiated | Guggenheim | Buy |
| Aug-14-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-03-21 | Resumed | H.C. Wainwright | Buy |
| Sep-22-21 | Upgrade | WBB Securities | Buy → Strong Buy |
| Mar-04-21 | Initiated | Aegis Capital | Buy |
| Sep-04-19 | Upgrade | Wedbush | Neutral → Outperform |
| Jul-26-18 | Initiated | Citigroup | Buy |
| Apr-21-17 | Initiated | Raymond James | Strong Buy |
| Apr-17-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-11-17 | Resumed | Wedbush | Outperform |
| Feb-22-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-17 | Upgrade | WBB Securities | Sell → Hold |
| Dec-21-16 | Resumed | Leerink Partners | Outperform |
| Dec-19-16 | Initiated | H.C. Wainwright | Buy |
| Sep-23-16 | Downgrade | WBB Securities | Hold → Sell |
| Oct-09-15 | Upgrade | WBB Securities | Sell → Hold |
| May-11-15 | Initiated | Jefferies | Buy |
| May-11-15 | Initiated | Leerink Partners | Outperform |
| May-11-15 | Initiated | Needham | Buy |
| May-11-15 | Initiated | Wedbush | Outperform |
| Apr-23-15 | Initiated | WBB Securities | Sell |
View All
Cidara Therapeutics Inc Stock (CDTX) Latest News
Cidara Therapeutics Inc.’s volatility index tracking explainedCEO Change & Free High Return Stock Watch Alerts - newser.com
Using Ichimoku Cloud for Cidara Therapeutics Inc. technicals2025 AllTime Highs & Consistent Return Strategy Ideas - newser.com
What institutional flow reveals about Cidara Therapeutics Inc.Quarterly Trade Report & Verified Momentum Stock Alerts - newser.com
Cidara Therapeutics (NASDAQ:CDTX) Shares Gap Up on Analyst Upgrade - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Now Covered by JPMorgan Chase & Co. - MarketBeat
JP Morgan Initiates Coverage on CDTX with Overweight Rating | CD - GuruFocus
WBB Securities Issues Positive Forecast for Cidara Therapeutics (NASDAQ:CDTX) Stock Price - MarketBeat
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza - sharewise.com
Cidara Therapeutics Analyst Says Lead Influenza Candidate Is 'Strategically Attractive' - Benzinga
Why Cidara Therapeutics (CDTX) Is Up 12.4% After Breakthrough Therapy Status for Novel Flu Drug CD388 - Yahoo Finance
Cidara Therapeutics (NASDAQ:CDTX) Hits New 12-Month High Following Analyst Upgrade - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $150.00 - MarketBeat
Cidara Therapeutics Surges Ahead of ESWI 2025 Presentation and JP Morgan Coverage - Benzinga
Can machine learning forecast Cidara Therapeutics Inc. recovery2025 Geopolitical Influence & Intraday High Probability Alerts - newser.com
Cidara Therapeutics stock price target raised to $150 at H.C. Wainwright - Investing.com Canada
Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025 - The Manila Times
JP Morgan Initiates Coverage of Cidara Therapeutics (CDTX) with Overweight Recommendation - Nasdaq
How to build a dashboard for Cidara Therapeutics Inc. stockWeekly Risk Summary & AI Enhanced Trading Signals - newser.com
JPMorgan Initiates Coverage on Cidara Therapeutics With Overweight Rating, $200 Price Target - MarketScreener
Can Cidara Therapeutics Inc. (20D0) stock reach $200 price target2025 Major Catalysts & Fast Gain Stock Tips - newser.com
Forecasting Cidara Therapeutics Inc. price range with options data2025 Volatility Report & Stepwise Swing Trade Plans - newser.com
Biotech And Healthcare Stocks Hit 52-Week Highs: Is The Momentum Sustainable? - Nasdaq
Why Cidara Therapeutics Inc. stock could be next big winnerQuarterly Profit Summary & Long Hold Capital Preservation Tips - newser.com
Cidara Therapeutics' (CDTX) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Why Cidara Therapeutics Stock Crushed It Today - sharewise.com
HC Wainwright & Co. Maintains Cidara Therapeutics (CDTX) Buy Recommendation - Nasdaq
CDTX Surges on FDA's Breakthrough Therapy Designation - GuruFocus
Why Cidara Therapeutics Stock Crushed It Today - The Motley Fool
Cidara Therapeutics Surge: Time to Dive In? - StocksToTrade
FDA grants breakthrough therapy status to Cidara’s influenza drug By Investing.com - Investing.com Nigeria
CDTX Analyst Rating Update: WBB Securities Raises Price Target | - GuruFocus
Cidara Therapeutics stock hits 52-week high at 106.71 USD By Investing.com - Investing.com Nigeria
CDTX Achieves New Heights: What’s Next? - timothysykes.com
Cidara Therapeutics Granted FDA Breakthrough Therapy Designation For Flu-Preventing Antiviral - Stocktwits
Cidara wins FDA “Breakthrough” status for CD388 - The Pharma Letter
HC Wainwright Maintains Buy Rating on CDTX, Raises Price Target - GuruFocus
HC Wainwright Raises Cidara Therapeutics' Price Target to $150 From $110, Buy Rating Kept - MarketScreener
Cidara Therapeutics stock hits 52-week high at 106.71 USD - Investing.com India
Cidara Therapeutics (CDTX) Gains FDA Breakthrough Designation fo - GuruFocus
Cidara Therapeutics Receives FDA Breakthrough Therapy Designation for CD388 as Prophylactic Against Influenza A and B - Quiver Quantitative
Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy - GlobeNewswire
Breakthrough Therapy for CD388 Granted; Cidara Advances Phase 3 ANCHOR Trial Expanded to Older Adults - Stock Titan
What hedge fund moves indicate for Cidara Therapeutics Inc. (20D0) stock2025 Sector Review & Fast Exit/Entry Strategy Plans - newser.com
How Cidara Therapeutics Inc. (20D0) stock performs in volatility spikesJuly 2025 Sentiment & Weekly Market Pulse Alerts - newser.com
Is Cidara Therapeutics Inc a good long term investmentDividend Reinvestment Plans & Big Profit Low Investment - earlytimes.in
Cidara Therapeutics (NASDAQ:CDTX) Shares Up 5.5%Time to Buy? - MarketBeat
Cidara announces funding for non-vaccine flu preventive, CD388 - CIDRAP
How Cidara Therapeutics Inc. (20D0) stock reacts to Fed tightening2025 Volatility Report & Real-Time Chart Pattern Alerts - newser.com
How buyback programs support Cidara Therapeutics Inc. (20D0) stockCEO Change & Short-Term High Return Ideas - newser.com
Will Cidara Therapeutics Inc. outperform the marketBull Run & Low Drawdown Investment Ideas - newser.com
Biotech Stocks To Research – October 3rd - Defense World
Cidara Therapeutics Inc Stock (CDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cidara Therapeutics Inc Stock (CDTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jun 26 '25 |
Buy |
44.00 |
2,272,727 |
99,999,988 |
3,365,523 |
| Mineo Chrysa | Director |
Jun 02 '25 |
Buy |
21.71 |
2,270 |
49,281 |
2,270 |
| Mineo Chrysa | Director |
Jun 03 '25 |
Buy |
23.44 |
1,050 |
24,614 |
3,320 |
| Ward Shane | COO & CLO |
Mar 11 '25 |
Sale |
21.96 |
1,664 |
36,542 |
14,674 |
| Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Mar 11 '25 |
Sale |
21.96 |
1,773 |
38,940 |
16,215 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):